EPHX2 and lung cancer: Knockdown of 16 of 18 (89%) CPD genes reduced viability in both cell lines (Fig. 5h)—including five targets not previously implicated in lung cancer (Ephx2, Peg3, Apob, Oit1 and Slc6a19; Supplementary Table 7).